AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.

AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.